17,261 trials
Clinical Stage III Cutaneous Melanoma AJCC v8 · Pathologic Stage III Cutaneous Melanoma AJCC v8 · Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Primary: Pathologic Complete Response Rate (pCR) — 66.7; 13.3; 38.2 percentage of participants
Gingivitis
Primary: Number Bleeding Sites — 31.52; 25.90; 21.65; 19.13 number of bleeding sites
Cancer of Unknown Primary Site
Primary: Overall Response Rate (ORR) by RECIST Criteria v1.1 in the Second-line & First-line Setting. — 0; 4; 9; 13 Participants
Diabetes Mellitus, Type 2
Primary: HbA1c — 8.21; 8.16 HbA1c percentage — p=.855
Traumatic Brain Injury
Primary: Determine Improvement in Somatic, Cognitive, and Emotional Post-concussion Symptoms as Measured by the Rivermeade Post-concussion Questionnaire (RPQ) in Treatment Group…
Tuberculosis, Multidrug-Resistant · Tuberculosis · Tuberculosis, Pulmonary
Primary: Time to 26 Weeks Stable Culture Conversion in Liquid Media — 8; 12 Weeks — p=0.0546
Dry Eye Syndrome
Primary: Sign: Corneal Fluorescein Staining Score — -1.06; -1.16 score on a scale
Alcohol Use Disorder · Sexually Transmitted Diseases
Primary: Number of Binge Drinking Days — 2.15; 2.15; 1.94; 2.21 number of days
Advanced Solid Tumors · Non-small Cell Lung Cancer
Primary: Maximum Tolerated Dose — 250 mg
Mild to Moderate Hypertension
Primary: Number of Participants With Adverse Events (AEs) — 6; 6; 4; 0 Participants
BRAF V600E · Metastatic Colorectal Cancer
Primary: Safety Lead-in Phase (SLI): Incidence of Dose Limiting Toxicities (DLTs) — 0 Participants
Liver Transplant · Hepatitis C
Primary: Adverse Events Due to Sofosbuvir/Velpatasvir (Epclusa) — 0; 0 Participants
Discrimination, Racial · Communication · Chronic Illness
Primary: 10-item Connor-Davidson Resilience Scale (CD-RISC) — 0.67; 0 average of number of units on a scale
Pulmonary Aspergillosis
Primary: Proportion of Participants Who Completed 12 Weeks of Therapy — 47; 23 Participants
Anal Intraepithelial Neoplasia · High Grade Squamous Intraepithelial Neoplasia · HIV Positivity
Primary: Overall Response Rate at 48 Weeks — 10 Participants